PhaseBio Pharmaceuticals Total Revenue

The latest total revenue for PHAS is $820K as of June 2022. That compares with $11M in the prior-year period — down 92.3% year over year. That is below the Healthcare sector average of $11T. Investors often review this figure alongside PhaseBio Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, PHAS's total revenue moved from $11M to $820K — a 92.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PhaseBio Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, PHAS currently prints $820K for total revenue, while the sector average sits near $11T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at PhaseBio Pharmaceuticals's growth, margins, and balance sheet.

A total revenue figure of $820K for PHAS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $11T. Explore the charts below for those layers of context.

After noting PHAS's total revenue ($820K), review year-over-year change from $11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.